Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial

Background Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks. Consequently, there is little evidence-based guidance for clinicians when...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Jess Kerr-Gaffney, Zohra Zenasni, Kimberley Goldsmith, Nahel Yaziji, Huajie Jin, Alessandro Colasanti, John Geddes, David Kessler, R Hamish McAllister-Williams, Allan H Young, Alvaro Barrera, Lindsey Marwood, Rachael W Taylor, Helena Tee, Anthony J Cleare
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	NIHR Journals Library 2025-05-01
سلاسل:	Health Technology Assessment
الموضوعات:	depression depressive disorder major antidepressive agents lithium quetiapine fumarate antipsychotic agents randomised controlled trial
الوصول للمادة أونلاين:	https://doi.org/10.3310/YQVF5347
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!